Todays tweets are very interesting and disappointing at the same time | PVCT Message Board Posts


Provectus Biopharmaceuticals, Inc.

  PVCT website

PVCT   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  58567 of 58733  at  1/30/2023 10:38:57 AM  by

canis_star


Todays tweets are very interesting and disappointing at the same time

Don't speculate and understand exactly what they are saying and stick to facts.....I will be very surprised if we achieve anything significant in 2023 (The so called achievements will be on the similar lines as 2022/2021).
 
17b/ $PVCT ➧ Focus (1): We plan to pursue a regulatory pathway for rare disease in-transit melanoma (a distinct sub-population of Stage III cutaneous melanoma) with monotherapy, intratumoral, small molecule, cancer immunotherapy PV-10® 
 
They are planning.....not pursued
 
17d/ Regulatory/RCT clinical in oncology (melanoma, to start) are $PVCT’s priorities, while also seeking to demonstrate our potentially expansive halogenated xanthene (#rosebengalsodium) medical science platform for other diseases.
 
Starting RCT clinical trial is their priority (I think they may start P2/3 RCT trial in 4Q2023). Does anyone even dare to guess when they will have data from this trial ? if we get decent clinical dataset by the end of 2025 they might be over achievers based on past performance.
 
17e/ $PVCT ➧ Focus (3): We plan to receive readouts of ongoing and new preclinical research. #research. #rosebengal #rosebengalsodium.
 This adds zero value IMO
 
17f/ An additional $PVCT clinical pursuit is metastatic #uvealmelanoma. Disease that is injectable via the liver (i.e., hepatic mets). NCT00986661 #livercancer. The initial work was done under the study’s Expansion Cohort 1: PV-10 +/- checkpoint(s). e.g., provectusbio.com/media/docs/pub….
17g/ $PVCT’s preparation of follow-on work for hepatic #uvealmelanoma mets is ongoing; would be under NCT00986661 EC3: PV-10 + checkpoint(s). Our data analysis and assessment were not complete prior to the 2023 stockholder letter, and not ready to communicate yet.
At best they says this indication is ready for RCT combo trial (I dont think this will move any further). Similar to mNET P2 combo trial that is waiting to start for last 2 and half years or pediatric clinical trials.   
 
Overall not very hopeful for significant news in 2023, unfortunately still lot of pep talk and speculation on paper but very little material progress made over the last 6 years.
 
 
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 1  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
58569 Re: Todays tweets are very interesting and disappointing at the same time canis_star 0 1/30/2023 11:04:33 AM




Financial Market Data provided by
.
Loading...